Hadlima Pushtouch

Biosimilar of:


Active Ingredient: adalimumab

Drug Class: Biologics

Hadlima Pushtouch is not covered on the Reformulary. Reformulary Group has selected specific adalimumab biosimilars to be covered: AMGEVITA, manufactured by Amgen, and HULIO, manufactured by Viatris. AMGEVITA and HULIO are considered preferred biosimilars as they offer the same clinical value at a lower net cost to the plan. AMGEVITA and HULIO require Special Authorization.

Hadlima Pushtouch is used to treat  
Ankylosing Spondylitis
Hidradenitis Suppurativa
Inflammatory Bowel Disease (IBD)
Juvenile Idiopathic Arthritis
Psoriatic Arthritis
Rheumatoid Arthritis